Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study
International Journal of Hematology · 2024
DOI: 10.1007/s12185-024-03805-0 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Yosuke Minami und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, National Cancer Center Hospital East, Chiba, Kashiwa, 277-8577, Japan. yominami@east.ncc.go.jp. Hauptthemen laut MEDLINE: Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma K.K..
Abstract (Originalsprache)
Asciminib is a first-in-class BCR::ABL1 inhibitor that Specifically Targets the ABL1 Myristoyl Pocket (STAMP). It is approved worldwide and in Japan for chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to previous tyrosine kinase inhibitor (TKI) therapy. In the Phase 3 ASCEMBL study, patients with CML-CP who received ≥ 2 prior ATP-competitive TKIs were randomized (2:1) to asciminib 40 mg twice-daily or bosutinib 500 mg once-daily. Here, we report the 96-week results of the subgroup analysis of Japanese patients (asciminib, n = 13; bosutinib, n = 3) in the ASCEMBL study. The MMR rate at Week 96 was 46.2% in asciminib-treated patients, increasing from Weeks 24 and 48. Patients who achieved MMR at Week 24 remained in MMR up to the Week 96 cutoff. While a high proportion of patients treated with asciminib remained on treatment at cutoff, none randomized to bosutinib were on treatment at Week 96. Despite the longer duration of exposure to asciminib, its safety and tolerability continued to be favorable with no new or worsening safety findings. Overall, the efficacy and safety outcomes in the Japanese subgroup were comparable with the ASCEMBL global study population, which supports the use of asciminib in Japanese patients with previously treated CML-CP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, National Cancer Center Hospital East, Chiba, Kashiwa, 277-8577, Japan. yominami@east.ncc.go.jp.
- Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
- Kobe University Hospital, Kobe, Japan.
- Osaka University Hospital, Osaka, Japan.
- Osaka International Cancer Institute, Osaka, Japan.
- Fujita Health University School of Medicine, Toyoake, Japan.
Förderung
- Novartis Pharma K.K.
Zitieren
APA
Minami, Y., Doki, N., Matsuoka, H., Yokota, T., Tomita, A., Takahashi, N., Kubo, K., Goto, T., Kirito, K., Maki, A., Aoki, M., Dawson, M. K., & Matsumura, I. (2024). Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03805-0
Vancouver
Minami Y, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, et al. Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03805-0
BibTeX
@article{Minami2024,
author = {Minami, Yosuke and Doki, Noriko and Matsuoka, Hiroshi and Yokota, Takafumi and Tomita, Akihiro and Takahashi, Naoto and Kubo, Kohmei and Goto, Tatsunori and Kirito, Keita and Maki, Akio and Aoki, Makoto and Dawson, Meryem Ktiouet and Matsumura, Itaru},
title = {Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study},
journal = {International Journal of Hematology},
year = {2024},
doi = {10.1007/s12185-024-03805-0}
}
EUVIMED